ライフサイエンスコーパス: PET image

1 ineation method used to outline tumor on the PET image.

2 atomic CT and then applied to the unsmoothed PET images.

3 to-healthy organ contrast and higher quality PET images.

4 ly with regional amyloid burden in congruent PET images.

5 ntially enable tumor visualization in static PET images.

6 veloped to measure tumor volume in (18)F-FDG PET images.

7 physical limit on the spatial resolution of PET images.

8 rocessing, leading to quantification bias in PET images.

9 mbrane antigen [PSMA]) is a novel ligand for PET imaging.

10 e scanned repeatedly with [(11)C]carfentanil PET imaging.

11 nflammatory leukocyte signal using (18)F-FDG PET imaging.

12 -Pittsburgh compound B (PiB) and 18F-MK-6240 PET imaging.

13 n between phosphorylated tau in CSF with tau PET imaging.

14 cult in some patients referred for (18)F-FDG PET imaging.

15 ivo binding in the rat, and nonhuman primate PET imaging.

16 ion and quantification of this protein using PET imaging.

17 asible and should be considered for coronary PET imaging.

18 ted to confirm engrafted islet numbers after PET imaging.

19 ed data were correlated with tumor uptake by PET imaging.

20 tumors, as demonstrated by RGD-based in vivo PET imaging.

21 inhibitors via noninvasive and quantitative PET imaging.

22 ilability was indexed using [(11)C]Ro15-4513 PET imaging.

23 Antibodies are promising vectors for PET imaging.

24 orination, autoradiography, and small-animal PET imaging.

25 as (225)Ac and (227)Th are incompatible with PET imaging.

26 18)F-rhPSMA-7.3 are considered favorable for PET imaging.

27 8) F radionuclide incorporation required for PET imaging.

28 f clinical sites that can perform diagnostic PET imaging.

29 logy with MIBG and the general advantages of PET imaging.

30 iable quantification of neuroinflammation by PET imaging.

31 ith [(11)C]PiB positron emission tomography (PET) imaging.

32 radioprobe for positron emission tomography (PET) imaging.

33 )Y tracers for positron emission tomography (PET) imaging.

34 diotracers for positron emission tomography (PET) imaging.

35 [(11)C]PK11195 positron emission tomography (PET) imaging.

36 flammation was assessed using [(11)C]PK11195 PET imaging, a marker of microglial activation.

37 subset of patients with interval metabolic (PET) imaging after initial chemotherapy, complete metabo

38 f [(89)Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients with CD44-positive tumors

39 CDKi) was evaluated and validated as a novel PET imaging agent to quantify CDK4/6 expression in estro

40 prostate-specific membrane antigen (rhPSMA) PET imaging agent, (18)F-rhPSMA-7.3.

41 on the uptake by tumor cells of (18)F-FDG, a PET imaging agent.

42 and brain uptake of the corresponding (64)Cu PET imaging agent.

43 g to develop a positron emission tomography (PET) imaging agent for the GluN2B subunits of the N-meth

44 eport a (64)Cu positron emission tomography (PET) imaging agent that shows appreciable in vivo brain

45 ium, and its role in drugs for radiotherapy, PET imaging agents and perspectives for applications in

46 Previously reported PET imaging agents targeting CXCR4 suffer from either hi

47 uture academically sponsored NDA filings for PET imaging agents.

48 uitable for further development as oncologic PET imaging agents.

49 PET imaging allowed us to identify the compound [(68)Ga]

50 Conclusion: (18)F-BMS-986192 PET imaging allows detection of membrane-expressed PD-L1

51 PET imaging allows dynamic observation of the bio-distri

52 igated whether positron emission tomography (PET) imaging allows identification of altered metabolic

53 ing and rapid normal tissue clearance of the PET imaging analog (86)Y-NM600.

54 Results: PET images and ex vivo biodistribution in immunocompeten

55 image and sinogram space from low-dose (LD) PET images and sinograms without sacrificing diagnostic

56 thods: NM600 was radiolabeled with (86)Y for PET imaging and (177)Lu for targeted radionuclide therap

57 PET imaging and biodistribution studies showed high tumo

58 PET imaging and biodistribution studies showed that the

59 on their in vitro performance, small-animal PET imaging and biodistribution studies were performed o

60 For PET imaging and biodistribution studies, a C4-2 tumor-be

61 evaluating the prognostic value of (18)F-FDG PET imaging and compared it with histologic grading.

62 e as radiochemical twins for both diagnostic PET imaging and endoradiotherapy.

63 PET imaging and ex vivo autoradiography revealed more pa

64 ect utility of this protocol for preclinical PET imaging and its translation to automated radiosynthe

65 facilitate a personalized medicine approach, PET imaging and quantification of mAbs, after chelation

66 stably be labeled with (89)Zr for whole-body PET imaging and quantification.

67 t acquisition and high spatial resolution of PET imaging and the intense uptake in tumor lesions, fac

68 2 and 3 position as potential candidates for PET imaging and/or therapy.

69 (high density EEG and 18F-fluorodeoxyglucose PET imaging) and structural (diffusion tensor imaging MR

70 re manually contoured on coregistered CT and PET images, and each was assigned an miPSMA score as per

71 ofiles and pharmacokinetics are suitable for PET imaging, and absorbed dose estimates are comparable

72 nd FLAIR volumetric MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University Coll

73 , subjects also received florbetapir amyloid PET imaging, and underwent a neuropsychological test bat

74 adiomics features extracted from oncological PET images are currently under intense scrutiny within t

75 high diagnostic performance when both CT and PET images are used.

76 In PET, images are created from the 511 keV photons produce

77 highlights the potential utility of the OX40 PET imaging as a new strategy for GvHD diagnosis and the

78 to detect tau pathology in AD patients using PET imaging, as well as to assess its safety and tolerab

79 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerab

80 get organs were determined directly from the PET images at 8 time points, and normalized time-activit

81 n = 13) followed by dual MEMRI and (18)F-FDG PET imaging at 10-12 weeks.

82 PET imaging at 8 wk post-AAV delivery showed an increase

83 PET imaging at late time points after injection may allo

84 PET imaging at multiple time points (0-72 h) was perform

85 PET imaging-based estimates were less variable and more

86 tion was performed in Wistar rats comprising PET imaging, biodistribution, receptor occupancy, and me

87 uld serve as a positron emission tomography (PET) imaging biomarker for HD therapeutic development an

88 d emerging conventional nuclear medicine and PET imaging biomarkers, as the diagnostic nuclear medici

89 ionuclides for positron emission tomography (PET) imaging, but also capture the potentially released

90 he accuracy of the mu-maps and reconstructed PET images by performing voxel- and region-based analysi

91 ng (64)Cu(2+), positron emission tomography (PET) imaging can be achieved for in vivo real-time and q

92 and its (134)La daughter) could be used as a PET imaging candidate for (225)Ac(III) (with reduced (13

93 PET imaging confirmed excellent tumor specificity for [(

94 Dynamic PET imaging confirmed PSMA-specific (as demonstrated by

95 ic vesicle glycoprotein 2A radiotracers with PET imaging could provide a way to measure synaptic dens

96 (64)Cu-Macrin PET imaging could stage inflammatory cardiovascular dise

97 previously acquired human [(11)C]carfentanil PET imaging data (132 male and 72 female healthy subject

98 We examined the PET imaging data of serotonin transporter occupancy by S

99 te tumor accumulation was EGFR-specific, and PET imaging data showed a clear differentiation between

100 earning algorithm to a multiparametric brain PET imaging dataset acquired in a cohort of 20- to 82-ye

101 usion: Kinetic analysis of dynamic (18)F-Gln-PET images demonstrated the ability to measure V(D) to e

102 18F-DOPA PET imaging demonstrated a significantly increased uptak

103 Small-animal PET imaging demonstrated high tumor uptake within 20 min

104 ptake in the remote noninfarcted myocardium (PET image-derived ratio of infarct uptake to remote upta

105 Performing PET imaging during ongoing radionuclide therapy can be a

106 The use of (18)F-BnTP PET imaging enabled us to functionally profile mitochond

107 PET imaging enables investigation, quantification, and t

108 in Wistar rats by in vitro autoradiography, PET imaging, ex vivo biodistribution, metabolite experim

109 Subsequent radiolabelling and in vivo PET imaging experiments in a small animal model demonstr

110 ensus by 2 experienced oncologists masked to PET imaging findings, was used as a reference standard.

111 re use in vivo positron emission tomography (PET) imaging, flow cytometry, and confocal microscopy to

112 Here, (18)F-fluorodeoxyglucose ((18)F-FDG) PET images for 441 oesophageal cancer patients (split: t

113 ontrols (HC) underwent dynamic (18)F-PI-2620 PET imaging for 180 min.

114 ntrols (HCs) underwent dynamic (18)F-PI-2620 PET imaging for 180 min.

115 bicentric pivotal phase 3 clinical trial for PET imaging for prostate cancer.

116 the long-term prognostic value of (18)F-FDG PET imaging for risk stratification of NENs and compare

117 We obtained paired FBB and FMM PET images from 107 participants.

118 standard for in vivo quantification, bias in PET images has been inferred using physical phantoms, ev

119 Somatostatin receptor PET imaging has had a profound effect on the evaluation

120 Tau PET imaging has potential for elucidating changes in the

121 [(18)F]FDOPA PET imaging has shown dopaminergic function indexed as K

122 ards this end, positron emission tomography (PET) imaging has emerged as one of the most informative

123 PET imaging identified significantly higher left ventric

124 t promising compounds were used for clinical PET imaging in 8 cancer patients.

125 chizophrenia patients using [(11)C]Ro15-4513 PET imaging in a cross-sectional, case-control study des

126 Conclusion: Using (18)F-flortanidazole PET imaging in a non-small cell lung cancer xenograft mo

127 y, we measured tau accumulation using AV1451 PET imaging in a subset of 87 participants.

128 the effect of AB treatment on (68)Ga-PSMA-11 PET imaging in hormone-naive (luteinizing hormone-releas

129 PET imaging in mice showed specific uptake of (18)F-olap

130 radiotracer, with optimized brain uptake by PET imaging in nonhuman primates.

131 ly seen on interictal 18F-fluorodeoxyglucose PET imaging in patients with focal epilepsy-that inheren

132 essed the feasibility of using (18)F-SKI for PET imaging in patients with malignancies.

133 halamus, and hippocampus was demonstrated by PET imaging in rodents.

134 (CBF) and tau positron emission tomography (PET) images in independent discovery [cognitively normal

135 PET imaging is a sensitive and clinically relevant modal

136 e-specific membrane antigen (PSMA)-targeting PET imaging is becoming the reference standard for prost

137 Conclusion: GPM during coronary (18)F-NaF PET imaging is common and may affect quantitative accura

138 he potential diagnostic utility of (18)F-FES PET imaging is expected to be equally valid for patients

139 However, small-animal PET imaging is limited by coarse spatial resolution.

140 for diagnostic scintigraphy, especially when PET imaging is not available.

141 ts for HER2-targeting therapy in areas where PET imaging is not readily available.

142 imaging tools such as (89)Zr-Df-IAB22M2C for PET imaging is of prime importance to identify patients

143 lar and pathological processes on which TSPO PET imaging is reporting.

144 In vivo positron emission tomography (PET) imaging is a key modality to evaluate disease statu

145 Therefore, [(11)C]13 is a potential PET imaging ligand for mGluR2 in different central nervo

146 d as potential positron emission tomography (PET) imaging ligands for mGluR2 in the brain.

147 that quantification of amyloid-beta (Abeta) PET images may reduce interreader variability and aid in

148 ive neuropsychological assessments following PET imaging (mean number of cognitive visits = 2.8 +/- 1

149 mendous efforts have been made in developing PET imaging methods for pediatric brain tumors.

150 rs, and we used the tracking information for PET-image motion correction.

151 The (18)F-MAPP PET imaging noninvasively differentiated varying amounts

152 f radiomic features extracted from (18)F-FDG PET images of cervical tumors.

153 F-AlF-RESCA-IL2 yielded the highest-contrast PET images of target lymph nodes.

154 PET images of the ligand with the best outcome, (18)F-JK

155 By using PET imaging of (18)F-BnTP, we profile mitochondrial memb

156 We could also utilize PM-PBB3 for optical/PET imaging of a living murine tauopathy model.

157 Abeta) aggregates, leading to the successful PET imaging of amyloid plaques in the brains of 5xFAD mi

158 Methods: We developed and validated brain PET imaging of awake, freely moving mice.

159 Bioluminescence and PET imaging of B7H3-sr39tk CAR T cells confirmed complet

160 abeled lipophilic cations being used for the PET imaging of chemotherapy-induced cardiotoxicity and i

161 Conclusion: (11)C-PS13 shows promise for PET imaging of COX-1 in OvCa, and rapid translation for

162 ant models that indicate potential for human PET imaging of CSF1R and the microglial component of neu

163 (HC) participants completed [(11)C]-(+)-PHNO PET imaging of D2R and D3R availability and fMRI during

164 a-labeled FAP inhibitor ((68)Ga-FAPI-04) for PET imaging of fibroblast activation in a preclinical mo

165 (A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients wi

166 y be clinically relevant and exploitable for PET imaging of galectin-1-overexpressing bladder tumors.

167 Core body temperature, PET imaging of glucose uptake and VO(2) measurements con

168 to be the first appropriate radiotracer for PET imaging of human M(1) AChR.

169 tegrin recognition sequence that facilitates PET imaging of integrin upregulation during tumor angiog

170 uated an agonist tracer, (11)C-GR103545, for PET imaging of KOR in humans.

171 antagonist (11)C-LY2795050 radiotracers for PET imaging of KOR in humans.

172 nd metabolism in HCCs were analyzed by micro-PET imaging of mice; livers were collected and analyzed

173 nstrate successful CD38-targeted immunologic PET imaging of multiple myeloma in a murine model and in

174 , or (89)Zr-DFO-daratumumab, for immunologic PET imaging of multiple myeloma.

175 Furthermore, although PET imaging of neuroinflammation does not have an establ

176 This work advances PET imaging of NK cells and supports the translation of

177 PET imaging of PDE4 with (11)C-(R)-rolipram has been use

178 nd Drug Administration as the first drug for PET imaging of prostate-specific membrane antigen (PSMA)

179 Here, we demonstrate such a method using PET imaging of radiolabeled bevacizumab.

180 4)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors,

181 PET imaging of the 18-kDa translocator protein (TSPO) pr

182 PET imaging of translocator protein 18 kDa (TSPO) permit

183 rs (FAPIs) have been successfully applied to PET imaging of various tumor types.

184 FAP is a new target molecule for PET imaging of various tumors.

185 Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO),

186 in our review emphasized the impact of PSMA PET images on therapy management in prostate cancer pati

187 Conclusion: The present method enables brain PET imaging on awake mice, thereby avoiding the confound

188 PET imaging on both scanners consisted of a list-mode ac

189 reduced scan duration in oncologic (18)F-FDG PET imaging on quantitative and subjective imaging param

190 gh compound B) and tau ((18) F-flortaucipir) PET imaging on the same participants.

191 In two studies using PET imaging, one empirical (Study 1: N = 144 males and f

192 xtensive simulation studies, the analyses of PET-imaging outcomes from the Alzheimer's Disease Neuroi

193 g that 1-L-[(18)F]FETrp may prove a valuable PET imaging probe for the Shh subgroup of medulloblastom

194 oethyl)-L-tryptophan (1-L-[(18)F]FETrp) as a PET imaging probe for this common malignant pediatric br

195 tiomers of (11)C-Me-NB1, a recently reported PET imaging probe that targets the GluN2B subunit of N-m

196 elled tryptophan derivatives are feasible as PET imaging probes in brain tumor patients with activati

197 [(18)F]FSPG PET imaging provides a sensitive noninvasive measure of

198 Purpose To identify potential PET image quality improvement by using a recently develo

199 PET image quality was assessed using a NEMA IQ phantom.

200 The lightweight anterior array coil reduced PET image quantification bias by more than 50% compared

201 In 5-day-old mice, (64)Cu-Macrin PET imaging quantified physiologically more numerous car

202 are currently successfully used for clinical PET imaging, radionuclide therapy, and radioguided surge

203 te-specific membrane antigen (PSMA)-targeted PET imaging recently emerged as a new method for the sta

204 low in a set of specific brain regions using PET imaging, recently nearly all studies on the DMN empl

205 Here, we studied the impact of advanced PET image reconstruction methods on BCR localization and

206 Quantitative data derived from a PET-image region-of-interest analysis, which was corrobo

207 f serving the dual role both as an effective PET imaging reporter and as a suicide switch for CAR T c

208 In line with its preclinical data, PET imaging resulted in clear visualization of the cance

209 CD8-IHC confirmed the PET imaging results.

210 (18)F-FDG PET imaging reveals over-activation induced metabolic ch

211 Results: Awake (motion-corrected) PET images showed an (18)F-FDG uptake pattern comparable

212 The reconstructed PET images showed clear evidence of sodium transport thr

213 PET images showed focal myocardial (18)F-FOL uptake colo

214 Results: PET imaging showed consistent tumor accumulation and ret

215 (18)F-FDG PET imaging shows these changes are accompanied by alter

216 orm all FreeSurfer neuroanatomic labels into PET image space, which were subsequently used to compute

217 s with LVV (n = 69) underwent 141 paired FDG-PET imaging studies at one and two hours per a delayed i

218 ptor occupancy studies and has potential for PET imaging studies in ALS patients and possibly other b

219 PET imaging studies in rats demonstrated that [(11)C]13

220 PET imaging studies in Wistar rats showed a similar hete

221 Biodistribution and small-animal PET imaging studies were performed in CB17 SCID and LNCa

222 PET imaging studies with (11)C-labeled 1 in both HD mice

223 In nonhuman primate PET imaging studies, dose-dependent receptor occupancy o

224 eparately to categorize responders in CT and PET imaging studies.

225 cholinesterase positron emission tomography (PET) imaging studies implicate cholinergic changes as si

226 rom a previous positron emission tomography (PET) imaging study in epilepsy with 18F-FA-85380, a spec

227 aim of this work was to explore (132)La as a PET imaging surrogate for (225)Ac using a DOTA-based, tu

228 to assess the performance of full-dose (FD) PET image synthesis in both image and sinogram space fro

229 nd shape features are the least sensitive to PET imaging system variations.

230 minimize radiomic feature variations across PET imaging systems.

231 The results suggest that novel PET imaging techniques can be applied to inform and opti

232 RP model identified the brain regions in tau PET images that contributed most to the AD classificatio

233 maceutical for positron emission tomography (PET) imaging that is used to image Parkinson's disease,

234 [(11)C]Biotin PET imaging therefore provides a dynamic in vivo map of

235 regional atlas in standard space, requiring PET images to be spatially normalized.

236 drawn using CT were overlaid onto registered PET images to extract time-activity curves.

237 (amyloid-beta) and (18)F-Flortaucipir (tau) PET images to identify amyloid-beta and tau networks acr

238 CNN and LRP algorithms can be used with tau PET images to identify informative features for AD class

239 n grade II-IV glioma who underwent (18)F-FET PET imaging to distinguish between TP and TRCs.

240 t this hypothesis, we used RGD-based in vivo PET imaging to evaluate wild-type (wt) and SHARPIN-defic

241 The use of (89)Zr-antibody PET imaging to measure antibody biodistribution and tiss

242 labeled pH-targeted peptide can be used as a PET imaging tool to assess therapy response within PDAC

243 aration of the positron-emission tomography (PET) imaging tracer 3'-deoxy-3'-fluorothymidine (FLT) fr

244 red as it enables reliable interpretation of PET images, use of PSMA uptake as an imaging biomarker f

245 ns in various organs were extracted from the PET images using manually defined regions of interest.

246 our was semi-automatically delineated in the PET images using the Fuzzy locally adaptive Bayesian alg

247 umor was semiautomatically delineated in the PET images using the fuzzy locally adaptive Bayesian alg

248 Conversely, PET imaging using (124)I showed background accumulation

249 PET imaging using (64)Cu-Macrin faithfully reported accu

250 We sought to explore if PET imaging using hydrophobic cyclic peptides that parti

251 ilability with positron emission tomography (PET) imaging using the mGlu5 receptor-specific radiotrac

252 EGFR-targeting positron emission tomography (PET) imaging using U87 tumor xenograft mouse model.

253 The quality of the predicted PET images was assessed by 2 nuclear medicine specialist

254 Finally, visual inspection of (18)F-PM-PBB3-PET images was indicated to facilitate individually base

255 Serial PET imaging was carried out over 8 wk to assess PKM2 exp

256 city, and time between initial treatment and PET imaging was evaluated.

257 city, and time between initial treatment and PET imaging was evaluated.

258 In assessing response to therapy, FDG-PET imaging was performed at baseline and +4 days follow

259 In assessing response to therapy, (18)F-FDG PET imaging was performed at baseline and 4 d after ther

260 (86)Y-NM600 PET imaging was performed on female BALB/C mice bearing

261 Subsequently, PET imaging was performed on immunodeficient mice xenogr

262 Methods: PET imaging was performed on rhesus monkeys at baseline

263 PET imaging was performed with the KOR selective agonist

264 ewly available positron emission tomography (PET) imaging, we examined whether a well-validated measu

265 and microdosed positron emission tomography (PET) imaging, we identified a series of highly potent, s

266 mpound-B (PiB) positron emission tomography (PET) imaging, we measured tau and Abeta in 124 cognitive

267 PET images were acquired at 3, 24, and 48 h after inject

268 Whole-body PET images were acquired at approximately 4, 24, and 48

269 cer was also studied in rhesus macaques, and PET images were analyzed with an arterial plasma input f

270 PET images were assessed for overall image quality, and

271 dard electrocardiogram-gated data) diastolic PET images were compared in 3 separate groups defined by

272 All PET images were independently reviewed by 2 nuclear medi

273 Dynamic PET images were obtained for 1 h beginning at the time o

274 was evaluated, and some illustrative patient PET images were obtained.

275 PET images were reconstructed using 2 methods: ordered-s

276 PET images were reconstructed with 4-mm voxels and 2-mm

277 For the phantom study, PET images were reconstructed with and without time of f

278 Whole-body PET images were taken from rats over 240 min after intra

279 ast-enhanced high-resolution CT or (18)F-FDG PET images were used for coregistration.

280 MR and (18)F-FET PET imaging were performed at baseline and after the sec

281 Mayo Clinic Study of Aging who underwent PiB PET imaging were studied.

282 e 1-h images or only the 3-h (64)Cu-DOTATATE PET images) were considered true if found on simultaneou

283 We compared tumor (18)F-FAC PET images with (14)C-gemcitabine levels, established ex

284 Conclusion: PET imaging with (11)C-methionine specifically identifie

285 Conclusion: PET imaging with (11)C-methionine specifically identifie

286 r (131)I-omburtamab therapy underwent immuno-PET imaging with (124)I-8H9 followed by (131)I-8H9 antib

287 Conclusion: PET imaging with (124)I-omburtamab antibody administered

288 PET imaging with (18)F-FDG followed by mathematic modeli

289 Fifty-two patients with HCC underwent PET imaging with (18)F-fluorodeoxyglucose, followed by (

290 PET imaging with (68)Ga-DOTA-E[c(RGDfK)](2) peptide at d

291 ld of theranostics now uses newer SSTR-based PET imaging with (68)Ga-DOTATATE or (68)Ga-DOTATOC as a

292 PET imaging with 18-kDa translocator protein (TSPO) enab

293 PET imaging with amino acid tracers in adults increases

294 PET imaging with radiolabeled drugs provides information

295 iously demonstrated the potential utility of PET imaging with the dopamine D(2) and D(3) receptor ago

296 explored for different tumor entities using PET imaging with the fibroblast activation protein inhib

297 ll lung cancer xenograft tumor hypoxia using PET imaging with the hypoxia tracer (18)F-flortanidazole

298 n humans using positron emission tomography (PET) imaging with the novel KOR agonist radiotracer [(11

299 y to increase the throughput of small-animal PET imaging without considerable loss of image quality o

300 We tested whether (18)F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of comb